TRex Bio

We are decoding human tissue biology to create revolutionary therapeutics. TRexBio is at the forefront of these efforts, combining multidisciplinary expertise across immunobiology, drug discovery, functional genomics, computational and translational biology to uncover ‘deep biology’ in human tissues. We are a team of experienced and passionate scientists, drug development experts, and industry leaders. We are committed to decoding the human tissue immune system and believe we are uniquely positioned to usher in breakthrough medicines with this approach. Johnston Erwin joined TRexBio in May 2021 as Chief Executive Officer. Matt Chrysler joined TRexBio in 2019 with 15 years of portfolio and commercial experience in both emerging and large biotechnology companies. We are using our Deep Biology Platform to identify novel therapeutics for the treatment of immune-mediated diseases. We are a team that welcomes differences in backgrounds, opinions and experiences.